Next Article in Journal
Resistance to the SDHI Fungicides Boscalid and Fluopyram in Podosphaera xanthii Populations from Commercial Cucurbit Fields in Spain
Next Article in Special Issue
Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
Previous Article in Journal
The Genus Leccinum (Boletaceae, Boletales) from China Based on Morphological and Molecular Data
Previous Article in Special Issue
Antifungal Combinations in Dermatophytes
Review

Role of Antifungal Combinations in Difficult to Treat Candida Infections

1
Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Buenos Aires, Argentina
2
Unidad de Parasitología, Sector Micología, Hospital J. M. Ramos Mejía, Buenos Aires, Argentina
Academic Editors: Patrick Schwarz and Eric Dannaoui
J. Fungi 2021, 7(9), 731; https://doi.org/10.3390/jof7090731
Received: 30 July 2021 / Revised: 27 August 2021 / Accepted: 2 September 2021 / Published: 6 September 2021
(This article belongs to the Special Issue Antifungal Combinations in Fungal Infections)
Candida infections are varied and, depending on the immune status of the patient, a life-threatening form may develop. C. albicans is the most prevalent species isolated, however, a significant shift towards other Candida species has been noted. Monotherapy is frequently indicated, but the patient’s evolution is not always favorable. Drug combinations are a suitable option in specific situations. The aim of this review is to address this problem and to discuss the role of drug combinations in difficult to treat Candida infections. A search for eligible studies in PubMed and Google Scholar databases was performed. An analysis of the data was carried out to define in which cases a combination therapy is the most appropriate. Combination therapy may be used for refractory candidiasis, endocarditis, meningitis, eye infections and osteomyelitis, among others. The role of the drug combination would be to increase efficacy, reduce toxicity and improve the prognosis of the patient in infections that are difficult to treat. More clinical studies and reporting of cases in which drug combinations are used are needed in order to have more data that support the use of this therapeutic strategy. View Full-Text
Keywords: Candida infections; antifungal combinations; management; amphotericin B; azoles; echinocandins Candida infections; antifungal combinations; management; amphotericin B; azoles; echinocandins
MDPI and ACS Style

Vitale, R.G. Role of Antifungal Combinations in Difficult to Treat Candida Infections. J. Fungi 2021, 7, 731. https://doi.org/10.3390/jof7090731

AMA Style

Vitale RG. Role of Antifungal Combinations in Difficult to Treat Candida Infections. Journal of Fungi. 2021; 7(9):731. https://doi.org/10.3390/jof7090731

Chicago/Turabian Style

Vitale, Roxana G. 2021. "Role of Antifungal Combinations in Difficult to Treat Candida Infections" Journal of Fungi 7, no. 9: 731. https://doi.org/10.3390/jof7090731

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop